




The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Provectus Biopharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 210% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	568
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,897
Liabilities, Non-Current	79
Other Assets	127
Other Compr. Net Income	75
Other Expenses	0
Other Liabilities	24
Other Net Income	-210
Other Revenues	336
Property and Equipment	3.0
Research and Development	1,897
Selling, General and Administrative Expense	3,734

Output Variable	Value in 1000 USD
Assets	698
Liabilities	7,000
Expenses	5,631
Revenues	336
Stockholders Equity	-6,303
Net Income	-5,505
Comprehensive Net Income	-5,468
BaseVar	6,975
ECR before LimitedLiability	-499%
Economic Capital Ratio	19%